Rafael Holdings reports Q3 net loss of $1.5M; invests $2.1M in Cyclo Therapeutics

Rafael Holdings, Inc.

2023-Q3 EPS reported -$0.14 revenue$211,000

Net loss from continuing operations $1.5M ($0.06/sh) vs $5.0M ($0.25/sh) year ago.
Cash, equivalents and marketable securities $82.4M as of April 30, 2023.
Made initial $2.1M investment in Cyclo Therapeutics and agreement to invest additional $5M.
R&D expenses fell to $0.7M from $1.4M on winding down early-stage programs.
General and administrative expenses $2.3M for Q3, including $0.6M stock-based comp.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Rafael Holdings, Inc. reported the third quarter of fiscal 2023 for the three months ended April 30, 2023 results: net income net loss from continuing operations of $1.5 million, or $0.06 per share, EPS $0.06 per share.

Period: the third quarter of fiscal 2023 for the three months ended April 30, 2023
Net income: net loss from continuing operations of $1.5 million, or $0.06 per share
EPS: $0.06 per share
Result: reported results

Exact text from the filing

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

View on SEC.gov

Browse all earnings releases →

Rafael Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-048570

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.